Key facts
- This page summarizes Marc Rubin's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2022, 17:48.
Marc Rubin - 05 Jan 2022 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- TTNP
- Reported as of
- 05 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 17:48:25 UTC
- Next SEC filing
- 25 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /S/ Marc Rubin
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Marc Rubin filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 05 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TTNP
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +65,000
- Change %
- Price
- $0.000000
- Shares after
- 65,000
- Date
- 05 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $1.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest as to 32,500 shares on July 5, 2022 with the balance to vest in equal monthly installments over the 18 months thereafter.